Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current and future developments in travelers' diarrhea therapy.

Hoonmo L Koo1, Herbert L DuPont

  • 1Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA.

Expert Review of Anti-Infective Therapy
|June 15, 2006
PubMed
Summary

Travelers

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Microbiome alterations during and after international travel.

Journal of travel medicine·2025
Same author

Leaders behind the launching of the international society of travel medicine, the journal of travel medicine and helping to define a new medical discipline.

Journal of travel medicine·2025
Same author

Re-visiting bismuth subsalicylate for the prevention of travellers' diarrhoea.

Journal of travel medicine·2025
Same author

Microbiota restoration therapies for recurrent <i>Clostridioides difficile</i> infection reach an important new milestone.

Therapeutic advances in gastroenterology·2024
Same author

The Importance of a Healthy Microbiome in Pregnancy and Infancy and Microbiota Treatment to Reverse Dysbiosis for Improved Health.

Antibiotics (Basel, Switzerland)·2023
Same author

The potential for development of clinically relevant microbial resistance to rifaximin-α: a narrative review.

Clinical microbiology reviews·2023

Area of Science:

  • Medical Microbiology
  • Travel Medicine
  • Infectious Diseases

Background:

  • Diarrhea is a primary health concern for international travelers to tropical and subtropical regions.
  • Despite extensive research, illness rates and consequences remain high, affecting an estimated 40% of travelers to developing nations.
  • Emerging evidence suggests potential long-term complications, such as postinfectious irritable bowel syndrome.

Purpose of the Study:

  • To evaluate novel approaches for the prevention and treatment of travelers' diarrhea.
  • To assess the efficacy and safety of rifaximin as a treatment option.
  • To consider the routine use of chemoprophylaxis for high-risk travelers.

Main Methods:

  • Review of recent evidence on travelers' diarrhea etiology, pathogenesis, and treatment.
  • Evaluation of rifaximin, a poorly absorbed antibacterial drug, for watery diarrhea syndrome.
  • Analysis of antibacterial drugs' effectiveness in shortening diarrhea duration.

Main Results:

  • Rifaximin offers a safe and effective treatment option for watery diarrhea, comparable to absorbed antibacterials.
  • Rifaximin has a favorable safety profile and limited potential to induce bacterial resistance.
  • Antibacterial drugs, including rifaximin, can shorten diarrhea duration by 1-2 days.

Conclusions:

  • Rifaximin presents a valuable therapeutic option for travelers' diarrhea with a good safety profile.
  • Routine chemoprophylaxis with antibacterials warrants consideration for travelers to high-risk areas.
  • Antibacterial agents remain the optimal treatment for bacterial enteropathogen-induced travelers' diarrhea.

Related Experiment Videos